DOCSLIB.ORG

Diuretic Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diuretic Therapy RECENT ADVANCE~3 IN DIURETIC THERAPY Proceedings of the Second · International Edrul® Symposium Sorrento, ltaly, 4-6 November 1B82 Editor: V.E. Andreucci ~ 1983 \3Y Excerpta Medica Contents Welcome K. Deck Opening address G. Salvatore 2 Introduction V.E. Andreucci 3 SESSION I: SPECIAL LECTURE Diuretic-induced potassium lass D. W. Seldin 9 SESSION II: PHARMACOLOGY AND , PHARMACOKINETICS Antihypertensive effects of chronic treatment with muzolimine in experimental hypertension B. Garthofj, W.-D. Busse, S. Kazda and G. Luckhaus 23 Discussion 36 Effects of muzolimine in microperfusion studies of loops of Henle in rats J. Greven and B. Kölling 37 Discussion 46 Review of relevant pharmacokinetic data relating to muzolimine W. Ritter 48 Discussion 53 Contents SESSION III: MUZOLIMINE IN PATIENTS WITH CARDIAC OEDEMAS Dose titration of muzolimine in patients with cardiac oedema R.J. Madoery, G. Halsband, R. Spiritoso, H. Mosca and R.J. Esper 57 Discussion 62 Camparisan of the efficacy and tolerance of furosemide and muzolimine in patients with cardiac oedema E. Branco de Araujo, Jr., R. Faccioli, F. Mandarano, Jr. and H. Proenra 65 Discussion 73 Lang-term therapy with muzolimine in patients with chronic cardiac failure M. Studlar and F.O. Gruber 74 Discussion 79 Camparisan of effects of repeated single doses of muzolimine and piretanide in patients with cardiac failure. A single-blind controlled study P. Zardini, E. Uslenghi, B. Bianchini, B. Ottello and P. Salvini 81 Lang-term treatment with muzolimine in patients with cardiac oedema. An open study G. Ziakas, G. Zioutas, T. Arvanitidis and W. Zurukzoglu 92 Discussion 101 Urinary excretion of water and solutes and haemodynamic effects induced by muzolimine in patients with heart failure F. Tartagni and B. Magnani 103 Discussion 111 Haemodynamic effects of a single administration of muzolimine into the pulmonary artery E. G. Rovelli and M. Carnovali 112 VI Contents SESSION IV: MUZOLIMINE IN HYPERTENSIVE PATIENTS Comparison of antihypertensive efficacy and tolerance of muzolimine and furosemide in a six-week controlled clinical study P. Jabur and S. Ferreira 119 Discussion 126 Comparison of the antihypertensive effects of methyldopa and muzolimine in arterial hypertension A. Pirrelli and M. Stella 127 Discussion 136 A comparison of muzolimine and indapamide in hypertension. Analysis of group data versus analysis of individual findings P. T. Scarpelli, S. Romano, C. Corti, F. Bigioli, E. Croppi, L. Scarpelli, M. Manne/li and A. Stinchetti 138 Comparison of muzolimine and indapamide in the treatment of high blood pressure G. Amabile, A. Egre, E. Perchicot and A. Serradimigni 149 Discussion 155 Long-term treatment with muzolimine in hypertensive patients A. Da/ Canton, D. Russo, R. Gallo, A. Papa, A. Caputo, C. Sjorza, A. Pepe and V.E. Andreucci 156 Discussion 165 Comparison of the effects of muzolimine and a fixed combination of hydrochlorothiazide and amiloride in mildly to moderately hypertensive patients P. Wicker and J. Clementy 168 Discussion 178 Efficacy and tolerance of long-term antihypertensive treatment with muzolimine. An open, multicentre trial M. Hanisch, H. Gansen and W. Gunsetmann 180 Discussion 193 VII Contents Comparative study of muzolimine and chlorthalidone as antihypertensive drugs Ch. Nachev, II. Tomov, V. Vlahov, G. Stancousheva, J. Kaloianova, V. Ghergova, V. Ba/eva, A. Elencova, S. Tsolov, I. A tanassov and N. Bakracheva 195 Long-term treatment of mild to moderate hypertension with muzolimine A. Martins, A. Serra-Coelho, R. Soares, C. R,abaral, J. Carvalho and M. Carrageta 204 Discussion 208 Twenty-four-hour ambulatory profiles of blood pressure reduction following muzolimine M. Carrageta, R. Soares, A. Martins and A. Serra-Coelho 211 Discussion 215 Comparative clinical study of muzolimine (BAY g 2821) and furosemide in hypertension with chronic renal failure M. Lucsko, M. Chaignon, P. Aubert and J. Guedon 217 Discussion 229 SESSION V: MUZOLIMINE IN PATIENTS WITH HEPATOGENIC ASCITES ANDIN PATIENTS WITH CHRONIC RENAL FAlLURE Treatment of oedema with a new diuretic A. Salta, R. Faedda, G. Soggia, N.A. 0/meo, L. Nieddu, G.F. Branca and E. Bartoli 235 Discussion 242 The use of muzolimine in chronic renal failure G. Orsoni, A. Di Felice, P. Cucudis, A. Vangelista, S. Stejoni and V. Bonomini 246 Discussion 256 Comparison of the diuretic effects of high doses of furosemide and muzolimine in patients with advanced chronic renal failure V. Mioli, M. Ragaiolo, E. Ohnmeiss and M. Carosi 259 VIII Contents Discussion 267 Muzolimine in children with renal oedema. A pilot study R. Genova and A. Guerra 269 Discussion 276 The use of muzolimine in dialysis patients. A pilot study on dialysability and adsorption on aluminium hydroxide H. Mann, M. Hanisch and W. Ritter 277 Discussion 282 Study of interactions between muzolimine and furosemide in patients on maintenance haemodialysis E. Weissehedei and E. Ritz 283 D~~oo m Muzolimine in patients with decompensated renal insufficiency and oedema resistant to furosemide N. Belovezhdov, A. Astrug, V. Vlahov, D. Tzekova, M. Vretenarska and N. Bakracheva 292 Discussion 298 POSTER SESSIONS Effects of muzolimine and furosemide in hypertensive pat:ients E. Angelucci, F. Capani, A. Dei Ponte, M. T. Guagnano and S. Sensi 301 Diuretic effects of muzolimine in patients with congestive heart failure. A comparison with furosemide L. Bartolucci, F. Canini, G. Antonelli, G. Vincenzoni, M. Formica, M. Carosi and C. Valori 306 Muzolimine in the treatment of uncontrolled essential arterial hypertension C. Beneitez 311 Comparison of the antihypertensive efficacy and acceptability of muzolimine and piretanide 0. de Divitiis, S. Di Somma, M. Petitto, S. Fazio, M. Galderisi and B. Villari 315 IX Contents The in vitra metabalism af muzalimine (BAY g 2:821) J. W. Gorrod and P.D. Messis 321 Efficacy and talerance af muzalimine in camparisan with furasemide in the treatment af cardiac aedema G. Montreuil and J. Jaillard 326 Camparisan af the antihypertensive and metabalilc effects af muzalimine and a cambinatian af hydrachlarathiazide and amilaride P. Strazzul/o, L.A. Ferrara, F. Galletti, Marcel/o Mancini, P. Mastranzo and M. Mancini 328 Clasing remarks V.E. Andreucci 335 Index af authars 337 Subject index 339 X .
Load more

Recommended publications
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Penetrating Topical Pharmaceutical Compositions Containing N-\2-Hydroxyethyl\Pyrrolidone
    Europaisches Patentamt ® J European Patent Office © Publication number: 0 129 285 Office europeen des brevets A2 (12) EUROPEAN PATENT APPLICATION © Application number: 84200823.7 ©Int CI.3: A 61 K 47/00 A 61 K 31/57, A 61 K 45/06 © Date of filing: 12.06.84 © Priority: 21.06.83 US 506273 © Applicant: THE PROCTER & GAMBLE COMPANY 301 East Sixth Street Cincinnati Ohio 45201 (US) © Date of publication of application: 27.12.84 Bulletin 84/52 © Inventor: Cooper, Eugene Rex 2425 Ambassador Drive © Designated Contracting States: Cincinnati Ohio 4523KUS) BE CH DE FR GB IT LI NL SE © Representative: Suslic, Lydia et al, Procter & Gamble European Technical Center Temseiaan 100 B-1820 Strombeek-Bever(BE) © Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone. Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration- enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and per- cutaneous delivery of the active selected. A method of treat- ing certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed. TECHNICAL FIELD i The present invention relates to compositions which enhance the utility of certain pharmaceutically-active agents by effectively delivering these agents through the integument. Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept.
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • Diuretics and Magnesium 87
    Magnesium-Bulletin 3/84 Reyes et al. I Diuretics and magnesium 87 Diuretics and magnesium By A. J. Reyes and W. P. Leary Universidad de la ~epublica and Fundaci6ri, Procardias, Montevideo, Uruguay, and University of Natal, Durban, South Afnca . Zusammenfassung brovasculaires ainsi qu'au developpe­ The chronic administration of Die chronische Gabe von Diuretika ment d'arythmies cardiaques pendant common diuretics at standard mit Angriffspunkt an der Henleschen )'infarctus aigu du myocarde et aux alte· rations du metabolisme lipidique et gluci­ doses may give rise to diverse Schleife oder am distalen Tubulus kann cardiac arrhythmias, including zur Mg-Verarmung des KOrpers fiihren. dique qui ont lieu pendant le traitement Das resultierende Mg-Defizit destabili­ diuretique. La prevention de ces effets ventricular fibrillation, or sudden siert die elektrische Erregbarkeit des indesirables des diuretiques doit etre death, and may also increase the Myokards und ist Hauptursache fiir das effectuee par une selection adequate de risks of myocardial infarction la substance diuretique, !'usage de doses Auftreten von Arrhythmien nach and of arrhythmias complicating Behandlung mit Diuretika. Der Mg-Man­ minimales, !'ingestion optimale de Na et gel fordert die Entwicklung von Erkran­ de Mg et !'administration de Mg chez acute myocardial infarction [74, kungen der Coronar- und Cerebralge­ certain malades. 81]. fiiBe, das Auftreten von Arrhythmien Classically, K-deficiency wiihrend des akuten Myokardinfarktes caused by common diuretics has und StOrungen des Lipid- und Kohlenhy­ been incriminated as the princi- · dratstoffwechsels bei Therapie mit Diure­ Modem diuretics may be clas­ tika. Diese unerwiinschten Nebenwirkun­ sified it;tto three groups. Loop pal pathogenic factor of arrhyth­ gen kOnnen vermieden werden durch diuretics such as furosemide, mias provoked by these drugs Auswahl von Diuretika, die keine ethacrynic acid, bumetanide, [62, 65, 68].
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • WO 2014/076235 Al 22 May 2014 (22.05.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/076235 Al 22 May 2014 (22.05.2014) P O P C T (51) International Patent Classification: (74) Agent: ICOSA; 83 avenue Denfert-Rochereau, F-75014 A61K 31/00 (2006.01) A61K 38/11 (2006.01) Paris (FR). A61K 31/196 (2006.01) A61P 25/28 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/7088 (2006.01) A61P 25/00 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/EP2013/073942 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 15 November 2013 (15.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (25) Filing Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (30) Priority Data: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 12193087.9 16 November 2012 (16. 11.2012) EP ZW. 61/727,235 16 November 2012 (16.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]